122 results on '"Moliterno, David"'
Search Results
2. Influence of Baseline Anemia on Dual Antiplatelet Therapy Cessation and Risk of Adverse Events After Percutaneous Coronary Intervention: Insights From the PARIS Registry
3. Tailoring Antiplatelet Therapy Intensity to Ischemic and Bleeding Risk: A Cost Consequence Simulation From PARIS
4. Antithrombotic Therapy in Patients With Atrial Fibrillation Treated With Oral Anticoagulation Undergoing Percutaneous Coronary Intervention: A North American Perspective–2018 Update
5. Incidence, Patterns, and Impact of Dual Antiplatelet Therapy Cessation Among Patients With and Without Chronic Kidney Disease Undergoing Percutaneous Coronary Intervention: Results From the PARIS Registry (Patterns of Non-Adherence to Anti-Platelet Regimens in Stented Patients)
6. Hybrid coronary revascularization: Time for a new comparator?
7. Clinical features and outcomes of patients with type 2 myocardial infarction: Insights from the Thrombin Receptor Antagonist for Clinical Event Reduction in Acute Coronary Syndrome (TRACER) trial
8. Abstract 17006: Tradeoff in Risks for Myocardial Infarction and Bleeding in Relation to Bleeding Risk: Insights From PARIS Registry
9. White Blood Cell Count and Major Adverse Cardiovascular Events After Percutaneous Coronary Intervention in the Contemporary Era: Insights From the PARIS Study (Patterns of Non-Adherence to Anti-Platelet Regimens in Stented Patients Registry)
10. Safety of an abbreviated duration of dual antiplatelet therapy (≤6 months) following second-generation drug-eluting stents for coronary artery disease: A systematic review and meta-analysis of randomized trials
11. Ageless benefits of transradial access for percutaneous coronary revascularization
12. Potential Hazards of Adding Nonsteroidal Anti-inflammatory Drugs to Antithrombotic Therapy After Myocardial Infarction: Time for More Than a Gut Check
13. 2012 American college of cardiology foundation/society for cardiovascular angiography and interventions expert consensus document on cardiac catheterization laboratory standards update: American college of cardiology foundation task force on expert consensus documents society of thoracic surgeons society for vascular medicine
14. Supplement to: Thrombin-receptor antagonist vorapaxar in acute coronary syndromes.
15. Vorapaxar in patients with peripheral artery disease and acute coronary syndrome: Insights from Thrombin Receptor Antagonist for Clinical Event Reduction in Acute Coronary Syndrome (TRACER)
16. The impact of left anterior descending coronary artery length on survival following myocardial infarction: To the apex and beyond
17. Revascularisation for patients with stable coronary artery disease
18. QRS duration predicts death and hospitalization among patients with atrial fibrillation irrespective of heart failure: evidence from the AFFIRM study
19. High-risk coronary anatomy versus high-risk physiology as outcome predictors in acute coronary syndromes
20. Optimal platelet inhibition in patients undergoing PCI: Data from the Multicenter Registry of High-Risk Percutaneous Coronary Intervention and Adequate Platelet Inhibition (MR PCI) study
21. Vorapaxar with or without clopidogrel after non–ST-segment elevation acute coronary syndromes: Results from the Thrombin Receptor Antagonist for Clinical Event Reduction in Acute Coronary Syndrome trial
22. Tissue necrosis factor α and targeting its receptor in ischaemic heart disease
23. Effect of vorapaxar on myocardial infarction in the thrombin receptor antagonist for clinical event reduction in acute coronary syndrome (TRA·CER) trial
24. Increased mortality among patients taking digoxin—analysis from the AFFIRM study
25. Remote ischemic preconditioning in elective percutaneous coronary intervention does not protect myocardium nor mobilize endothelial progenitor cells
26. D-055 Title: Regional Differences in Patterns of Dual Antiplatelet Therapy Cessation among Patients Undergoing Percutaneous Coronary Intervention 1-Year Insights From the PARIS Registry
27. Zotarolimus-Eluting Stents Among Patients With Renal Impairment Undergoing Percutaneous Coronary Intervention
28. Third universal definition of myocardial infarction
29. Early and late outcome associated with bleeding events in the setting of dual antiplatelet therapy following stent placement
30. 2012 ACCF/AATS/SCAI/STS expert consensus document on transcatheter aortic valve replacement: Developed in collabration with the American Heart Association, American Society of Echocardiography, European Association for Cardio-Thoracic Surgery, Heart Failure Society of America, Mended Hearts, Society of Cardiovascular Anesthesiologists, Society of Cardiovascular Computed Tomography, and Society for Cardiovascular Magnetic Resonance
31. Baseline NT-proBNP and biomarkers of inflammation and necrosis in patients with ST-segment elevation myocardial infarction: insights from the APEX-AMI trial
32. 2012 ACCF/AATS/SCAI/STS Expert Consensus Document on Transcatheter Aortic Valve Replacement: Developed in collaboration with the American Heart Association, American Society of Echocardiography, European Association for Cardio-Thoracic Surgery, Heart Failure Society of America, Mended Hearts, Society of Cardiovascular Anesthesiologists, Society of Cardiovascular Computed Tomography, and Society for Cardiovascular Magnetic Resonance
33. Contemporary occurrence of stent thrombosis in clinical practice: Better never than late
34. Creating Biodegradable-Polymer Drug-Eluting Stents: Shortening the Duration of Polymer and Dual Antiplatelet Therapy While Lengthening the Follow-Up‡
35. Thrombin-Receptor Antagonist Vorapaxar in Acute Coronary Syndromes
36. A Randomized Two-by-Two Comparison of High-Dose Bolus Tirofiban Versus Abciximab and Unfractionated Heparin Versus Bivalirudin During Percutaneous Coronary Revascularization and Stent Placement: The Tirofiban Evaluation of Novel Dosing versus Abciximab with Clopidogrel and Inhibition of Thrombin (TENACITY) Study Trial
37. Patient, Heal Thyself: The Ongoing Evolution of Patient Self-directed Care and Hand-Held Technology
38. Unfractionated Versus Low-Molecular-Weight Heparin for Primary Angioplasty—More Data Suggesting to Go Low
39. Editorial: Protein C and S Deficiency as a Risk Factor for Stent Thrombosis—When a Rare Disorder Can Predispose to Rare Events
40. Hormone replacement therapy among postmenopausal women presenting with acute myocardial infarction: Insights from the GUSTO-III trial
41. Rotational Atherectomy for Resistant Chronic Total Occlusions: Another Spin for Tough Old Problems
42. Tirofiban as adjunctive therapy for acute coronary syndromes and percutaneous coronary intervention: a meta-analysis of randomized trials
43. Contribution of angiographic and electrocardiographic parameters of reperfusion to prediction of mortality and morbidity after acute ST-elevation myocardial infarction:: Insights from the Assessment of Pexelizumab in Acute Myocardial Infarction trial
44. Left main and multivessel coronary artery stenting for patients deemed inoperable—A real need for a tandem approach
45. Options and outcomes with different antiplatelet strategies during primary percutaneous coronary intervention
46. Incidence, distribution, and prognostic impact of occluded culprit arteries among patients with non-ST-elevation acute coronary syndromes undergoing diagnostic angiography
47. Evaluation and management of thrombocytopenia and suspected heparin-induced thrombocytopenia in hospitalized patients: The Complications After Thrombocytopenia Caused by Heparin (CATCH) registry
48. Trifurcation left main coronary artery percutaneous revascularization—Pushing catheters and envelopes
49. Advances in Antiplatelet Therapy for ACS and PCI
50. ACCF/ACG/AHA 2008 Expert Consensus Document on Reducing the Gastrointestinal Risks of Antiplatelet Therapy and NSAID Use
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.